Nutriband (NASDAQ:NTRB) Issues Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Nutriband (NASDAQ:NTRB) announced its quarterly earnings results on Monday. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.06), Zacks reports. Nutriband had a negative net margin of 338.51% and a negative return on equity of 54.49%.

Nutriband Stock Up 9.8 %

NASDAQ:NTRB opened at $5.84 on Tuesday. The firm has a market capitalization of $64.86 million, a price-to-earnings ratio of -8.23 and a beta of 1.19. Nutriband has a 1-year low of $3.30 and a 1-year high of $11.78. The company has a current ratio of 4.96, a quick ratio of 4.83 and a debt-to-equity ratio of 0.01. The business’s fifty day moving average price is $6.05 and its 200 day moving average price is $5.72.

Analyst Upgrades and Downgrades

Separately, Noble Financial started coverage on shares of Nutriband in a research report on Wednesday, January 22nd. They issued an “outperform” rating and a $13.00 price objective for the company.

Nutriband Company Profile

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.